+1,470.5%
HUT vs MRNA
+537.9%
+932.6%
-95.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.4% | -3.6% | +9.9% | +6.8% |
| 7D | +28.3% | -9.0% | +37.3% | +29.5% |
| 30D | +12.3% | +137.2% | -124.9% | -10.0% |
| 3M | -16.8% | +194.8% | -211.6% | -36.8% |
| 6M | +111.4% | +167.2% | -55.8% | +63.9% |
| YTD | +116.6% | +375.9% | -259.3% | +50.3% |
| 1Y | +290.5% | +465.2% | -174.7% | +162.5% |
| 3Y | +792.3% | +30.4% | +761.9% | +624.6% |
| 5Y | +94.1% | -66.8% | +160.9% | +67.9% |
| All | +1,470.5% | +537.9% | +932.6% | +1,585.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling